Comparisons of therapeutic protocols and outcomes. Values are % unless otherwise specified.
| Variables | Groups | |||
|---|---|---|---|---|
| NC | SC | C1 | C2 | |
| Followup duration, median | ||||
| (IQR), mos | 30.5 (10.6–66.5) | 29 (10–52) | 29.5 (12–66) | 21.5 (8.3–32.25) |
| Induction treatment | ||||
| Methylprednisolone pulse | 13 | 20.4 | 15.7 | 35a |
| Prednisone | 23.7 | 10.2a | 17.2 | 10.2a |
| Prednisone + IVC | 13.6 | 27.1 | 29.7a | 46.9a,b,c |
| Prednisone + MMF | 40.7 | 32.2 | 31.3 | 20.4 |
| Prednisone + CNI | 16.9 | 20.3 | 15.6 | 10.2 |
| Prednisone + MMF + CNI | 5.1 | 10.2 | 6.2 | 12.2 |
| Maintenance treatment | ||||
| Prednisone | 26.2 | 10.6 | 19.1 | 12.9 |
| Prednisone + MMF | 45.2 | 34 | 34 | 25.8 |
| Prednisone + CNI | 19 | 21.3 | 17 | 12.9 |
| Prednisone + AZA | 4.8 | 6.4 | 6.4 | 9.7 |
| Prednisone + MMF + CNI | 0 | 10.6a | 6.4 | 16.1a |
| Others | 4.8 | 17 | 17 | 22.6a |
| Treatment response | ||||
| Complete remission | 72.5 | 54.5 | 56.7 | 34.8a,b,c |
| Partial remission | 19.6 | 30.9 | 38.3a | 41.3a |
| Treatment failure | 7.8 | 14.5 | 5.0 | 23.9c |
| Longterm prognosis | ||||
| Relapse | 30.0 | 24.4 | 37.5 | 29.7 |
| Doubling of SCr | 8.5 | 13.6 | 11.1 | 28.6a,c |
| ESRD | 6.8 | 6.8 | 7.8 | 18.4 |
↵a p < 0.05 compared with NC group.
↵b p < 0.05 compared with SC group.
↵c p < 0.05 compared with C1 group. IVC: intravenous cyclophosphamide; MMF: mycophenolate mofetil; CNI: calcineurin inhibitor; AZA: azathioprine; SCr: serum creatinine; ESRD: endstage renal disease; NC: noncrescent group; SC: segmental crescent group.